Current through Register Vol. 61, No. 4, April 1, 2022
(1) Any patient in comprehensive maintenance
treatment may receive a single take-home dose for a day that the clinic is
closed for business, including Sundays, and state or federal holidays.
Decisions on dispensing opioid
treatment medications to patients for unsupervised use shall be made by the
program medical director. In determining whether a patient is responsible in
handling opioid medications and may be permitted unsupervised use, the medical
director shall consider the following criteria;
(a) Absence of drugs of abuse, including
(b) Regularity of program
(c) Absence of serious
behavioral problems at the program;
(d) Absence of criminal activity while
enrolled at the program;
Stability of the patient's home environment and social relationships;
(f) Length of time in
comprehensive maintenance treatment;
(g) Assurance that take-home medication can
be safely stored in the patient's home; and
(h) Whether the rehabilitative benefit the
patient derives from decreasing the frequency of program attendance outweighs
the potential risks of diversion.
(3) Decisions to approve unsupervised use of
opioid medications, including the rationale for the approval, shall be
documented in the patient record.
If it is determined that a patient is
responsible in handling opioid agonist medications, the supply shall be limited
to the following schedule;
(a) During the
first 90 days of treatment, the take-home supply is limited to a single dose
each week, in addition to take-home doses allowed when the clinic is closed;
(b) During the second 90 days of
treatment, the take-home supply is limited to two doses per week, in addition
to take-home doses allowed when the clinic is closed;
(c) During the third 90 days of treatment,
the take-home supply is limited to three doses per week, in addition to
take-home doses allowed when the clinic is closed;
(d) In the remaining months of the first
year, a patient may be given a maximum 6-day supply of take-home medication;
(e) After one year of continuous
abstinence in treatment, a patient may be given a maximum two-week supply of
two years of continuous abstinence treatment, a patient may be given a maximum
one-month supply of take-home medication.
(5) The dispensing restrictions set forth in
4(a) through 4(f) of this rule do not apply to the partial agonist opioid
medication, buprenorphine and buprenorphine products. Patients must meet
criteria established in 2(a) through 2(h) of this rule for unsupervised use of
buprenorphine and buprenorphine products.
Or. Admin. R.
ADS 1-2003, f. 6-13-03,
cert. ef. 7-1-03; ADS 2-2008, f. & cert. ef. 11-13-08; ADS 1-2013(Temp), f.
1-11-13, cert. ef. 1-14-13 thru 7-12-13; ADS 5-2013, f. & cert. ef.
Stat. Auth.: ORS
Stats. Implemented: ORS